Elsevier Publishes Three New Encyclopedias on Mental

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Elsevier Publishes Three New Encyclopedias on Mental Health, Pharmacology and Forensic Medicine

New Reference Works Fill Content Gaps to Answer Challenging Questions and Improve Outcomes

CAMBRIDGE, MA --(Marketwired - November 18, 2015) - Elsevier , a world-leading provider of scientific, technical and medical information products and services, today announced the publication of three new encyclopedias -- the Encyclopedia of Mental Health , Meyler's Side Effects of Drugs , and the Encyclopedia of Forensic and Legal Medicine .

The second edition of the Encyclopedia of Mental Health , edited by Dr. Howard Friedman, provides up-to-date descriptions of the neurological, social, genetic, and psychological factors that affect the individual and society. It contains more than 240 articles written by domain experts in the field and is written in an accessible style using terms that an educated layperson can understand. The encyclopedia will be of interest to public as well as research libraries with coverage of many important topics, including marital health, divorce, couples therapy, fathers, child custody, day care and day care providers, extended families, and family therapy. It also provides essential material on assessment, theories of personality, specific disorders, therapies, forensic issues, ethics, and cross-cultural and sociological aspects. Dr. Friedman is Distinguished Professor of Psychology at the University of California, Riverside.

The 16 th edition of Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions , edited by Dr. Jeffrey Aronson, provides expanded coverage of each drug, with more than 1,500 drug articles and information on adverse reactions and interactions. It offers clearer, systematic organization of information for easier reading, including case histories to provide perspective on each listing and an extensive bibliography with more than 40,000 references. It is an appropriate reference work for any academic or medical library, pharmacologist, regulatory organization, hospital dispensary or pharmaceutical company. Dr. Aronson is a consultant clinical pharmacologist and physician in the Department of Primary Health Care in the University of Oxford and a consultant physician in the Oxford Radcliffe Hospitals Trust.

The Encyclopedia of Forensic and Legal Medicine , edited by Drs. Roger Byard and Jason Payne-James and now in its second edition, is a four-volume encyclopedia compiled by an international team of forensic specialists who explore the relationship between law, medicine, and science in the study of forensics. This reference work includes more than 300 chapters with articles covering autopsies, ballistics, fingerprinting, hair and fiber analysis, and the sophisticated procedures associated with terrorism investigations, forensic chemistry, DNA and immunoassays. It is suitable for any practitioner in a forensic, medical, healthcare, legal, judicial or investigative field looking for easily accessible and authoritative overviews on a wide range of topics. Dr. Byard holds the George Richard Marks Chair of Pathology at the University of Adelaide and is Senior Specialist Forensic Pathologist at Forensic Science SA in Adelaide, Australia. Dr. Payne-James is an independent specialist in forensic and legal medicine and has been a Forensic Medical Examiner with the Metropolitan Police Service in London, UK, for nearly 25 years.

Elsevier uses proprietary tools to identify knowledge gaps in fields such as psychology, pharmacology and forensic medicine. Editorial teams then strategically fill those gaps with content written by key influencers in the field, giving students, faculty, researchers and practitioners the content they need to answer challenging questions and improve outcomes. These new reference works are examples of how Elsevier is enabling science to drive innovation.

The encyclopedias are available on both the Elsevier Store and ScienceDirect, Elsevier's full-text scientific database offering journal articles and book chapters from over 2,500 peer-reviewed journals and more than 33,000 book titles.

Notes for Editors

ScienceDirect review access to the encyclopedias is available to credentialed journalists upon request. Contact Michelle McMahon at m.mcmahon.1@elsevier.com or +1 781 663 2268.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect , Scopus , Elsevier Research Intelligence and ClinicalKey -- and publishes over 2,500 journals, including The Lancet and Cell , and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc , a world-leading provider of information solutions for professional customers across industries. www.elsevier.com

Image Available: http://www.marketwire.com/library/MwGo/2015/1...35cd43.jpg
Image Available: http://www.marketwire.com/library/MwGo/2015/1...99d324.jpg
Image Available: http://www.marketwire.com/library/MwGo/2015/1...29ec28.jpg

Media contact Michelle McMahon Publicity Manager, Science & Technology Books Elsevier +1 781 663 2268 m.mcmahon.1@elsevier.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 10

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 71

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Rush to ExoraPad: The Rise of $EXP Tokens Explained

Updated Category News Views 219

Investors Flock to ExoraPad as the $EXP Token Presale Surges As the digital currency landscape evolves, many investors are seeking the next big opportunity. ExoraPad has emerged as a focal point in this space, particularly for those involved with XRP. The ongoing presale for the $EXP token has garnered immense attention, attracting numerous investors eager to secure their...

Continue Reading
Key Insights on DFDS A/S Share Transactions Involving Managers

Updated Category News Views 251

Recent Share Transactions by DFDS A/S Leadership On February 25, a significant transaction was recorded involving Claus V. Hemmingsen, the Chair of the Board of Directors for DFDS A/S, who purchased 5,000 shares of the company. This action showcases the confidence of the company’s leadership in its growth trajectory and operational strategy. Regulatory Obligations Under...

Continue Reading
First Guaranty Bancshares Reaches New Stock Milestone

Updated Category News Views 253

First Guaranty Bancshares Achieves New Milestone First Guaranty Bancshares Inc (NASDAQ: FGBI) has recently achieved a notable milestone, with its stock hitting a new 52-week high of $13.38. This impressive leap highlights a phase of robust growth for the company, reflected in the rising stock price that has been buoyed by favorable market sentiments. Over the past year,...

Continue Reading
Pho Hoa & Jazen Tea Expands Southeast with New Location

Updated Category News Views 314

Pho Hoa & Jazen Tea Expands into the Southeast Pho Hoa & Jazen Tea is excited to announce the grand opening of a new restaurant in Marietta, marking an important milestone in the brand's expansion strategy. With over 40 years dedicated to perfecting pho noodle soup, the company is eager to bring its incredible Vietnamese culinary experience to new customers. Exciting New...

Continue Reading
IDT Corporation's Commitment to Shareholders with New Dividend

Updated Category News Views 74

IDT Corporation Announces Quarterly Dividend for Shareholders IDT Corporation (NYSE: IDT), a key player in communications and payment services, has recently made waves by declaring a quarterly cash dividend of $0.05 per share. This news was shared through a regulatory filing, illustrating the company's ongoing commitment to providing value to its shareholders. Details on...

Continue Reading